

```

0      10      20      30      40      50      60      70      80      90
      GTCATCATGGGTGCTTCCCATTCAGGGGATGAGCTACCTGAGGAGTGTGGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCTGGTCAAGAGTCC
      GlyMetSerTyrLeuGluAspValArqLeuValHisArqAspLeuAlaAlaArqAsnValLeuValLysSerPr

100    CAACCATGTCAAATAACAGACTTCGGGCTGGCTGGACATTGACGAGACAGAGTACCATGCAGATGGGGCAAGGTTAGGTGAAGGACCAAG
      oAsnHisValLysIleThrAspPheGlyLeuAlaArqLeuAspIleAspGluThrGluTyrHisAlaAspGlyGlyLys


200    GAGCAGAGGAGGCTGGGTGGAGTGGTGTCTAGCCCATGGGAGAACTCTGAGTGGCCACCTCCCCACACACACAGTTGGAGGACTTCCTCTTCTGCCCTC

300    CCAGGTGCCCCATCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTTACCCACCAGAGTGTGTGGAGTTATGGTGTGATGGGGGGTGTG
      ValProIleLysTrpMetAlaLeuGluSerIleLeuArqArqPheThrHisGlnSerAspValTrpSerTyrGly

400    GGAGGGGTGGGTGAGGAGCCATGG
  
```

FIG. 1

FIG. 2



SEQUENCE COMPARISON WITH TYROSINE KINASE PROTEINS

	Homology	
pMAC117		* ** * * *
Human EGF R	85%	GMSYLEDVRLVHRDLAARNVLKSPNHVKITDFGLARLLDI
v-erb B	85%	N R T Q T Q K GA
v-src	52%	N ER T Q T Q K GA
v-abl	51%	A V RMNY R A I GENLVC VA I--
v-fms	50%	A E KKNFI C GENHL VA S MTG
Human Insulin R	42%	A F ASKNCI V LT GRVA G DI-M
		A NAKKF CM AHDF T G MS DT--

	Homology	
pMAC117		* * * * *
Human EGF R		DETEYHA-DG-GK--VPIKWMALLESILRRRFTHQSDVWSYGV
v-erb B		E K E E H IY H IY
v-src		EDN T RQ A F T P AA YG IK
v-abl		TYTA - A F T P LAYNK SIK F I
v-fms		NDSN IV K NAR L V P FDCVY V AF
Human Insulin Receptor		Y TD YR K GLL VR P LKDGV TS M F

FIG. 3

110791





FIG. 4

A



B





Figure 6

A



B





Figure 7

A



B




Figure 8





Figure 9






Figure 10